Skip to main content

Table 1 Characteristics of subjects stratified by hyperuricemia

From: Impact of monocyte to high-density lipoprotein ratio on prevalent hyperuricemia: findings from a rural Chinese population

Variables

Total (n = 8163)

Hyperuricemia (n = 1050)

Normouricemia (n = 7113)

P value a

Age (years)

54.13 ± 10.49

55.12 ± 10.96

53.99 ± 10.41

0.001

Males (%)

3731 (45.71)

652 (62.10)

3079 (43.29)

< 0.001

Race, Han (%)

7936 (97.22)

1033 (98.38)

6903 (97.05)

0.014

Education (%)

   

0.716

 Primary school or below

4322 (52.95)

561 (53.43)

3761 (52.88)

 

 Middle school

3134 (38.39)

393 (37.43)

2741 (38.54)

 

 High school or above

707 (8.66)

96 (9.14)

611 (8.59)

 

Income, CNY (%)

   

0.012

 ≤ 5000

851 (10.43)

134 (12.76)

717 (10.08)

 

 5000–20,000

4294 (52.60)

557 (53.05)

3737 (52.54)

 

 > 20,000

3018 (36.97)

359 (34.19)

2659 (37.38)

 

Physical activity (%)

   

0.101

 Low

3192 (39.10)

436 (41.52)

2756 (38.75)

 

 Middle

1547 (18.95)

205 (19.52)

1342 (18.87)

 

 High

3424 (41.95)

409 (38.95)

3015 (42.39)

 

 Current smoking (%)

2767 (33.90)

398 (37.90)

2369 (33.31)

0.003

 Current drinking (%)

1734 (21.24)

332 (31.62)

1402 (19.71)

< 0.001

 Height (cm)

160.66 ± 8.15

162.97 ± 8.45

160.32 ± 8.05

< 0.001

 Weight (kg)

63.49 ± 11.27

69.85 ± 12.16

62.56 ± 10.82

< 0.001

 BMI (kg/m2)

24.54 ± 3.61

26.26 ± 3.85

24.29 ± 3.50

< 0.001

 SBP (mmHg)

138.68 ± 21.93

144.79 ± 23.44

137.77 ± 21.55

< 0.001

 DBP (mmHg)

81.86 ± 11.64

86.09 ± 12.63

81.24 ± 11.35

< 0.001

 Scr (μmol/L)

73.80 (66.70–82.20)

82.70 (74.73–91.80)

72.80 (66.10–80.70)

< 0.001

 eGFR (ml/min per 1.73 m2)

89.33 ± 15.42

81.92 ± 19.13

90.42 ± 14.48

< 0.001

 FPG (mmol/L)

5.60 (5.22–6.10)

5.72 (5.32–6.35)

5.58 (5.22–6.06)

< 0.001

 TC (mmol/L)

5.32 ± 1.11

5.63 ± 1.28

5.27 ± 1.07

< 0.001

 TG (mmol/L)

1.29 (0.91–1.96)

1.88 (1.28–2.87)

1.23 (0.88–1.83)

< 0.001

 HDL-C (mmol/L)

1.34 ± 0.32

1.28 ± 0.33

1.35 ± 0.32

< 0.001

 LDL-C (mmol/L)

2.89 ± 0.80

3.07 ± 0.88

2.87 ± 0.79

< 0.001

 WBC count (109/L)

6.20 ± 2.06

6.61 ± 1.79

6.14 ± 2.09

< 0.001

 Lymphocyte count (109/L)

1.90 (1.60–2.40)

2.10 (1.70–2.50)

1.90 (1.60–2.30)

0.017

 Neutrophil count (109/L)

3.40 (2.70–4.30)

3.70 (2.90–4.60)

3.40 (2.60–4.20)

< 0.001

 Monocyte count (109/L)

0.41 (0.30–0.60)

0.50 (0.40–0.70)

0.40 (0.30–0.60)

< 0.001

 Lipid-lowering drug (%)

272 (3.33)

78 (7.43)

194 (2.73)

< 0.001

 History of CVD (%)

1268 (15.53)

222 (21.14)

1046 (14.71)

< 0.001

 SUA (μmol/L)

300.77 ± 85.68

452.12 ± 70.17

278.43 ± 61.79

< 0.001

 MHR

0.38 ± 0.25

0.45 ± 0.27

0.37 ± 0.24

< 0.001

  1. Data are expressed as mean ± standard deviation (SD) or median (interquartile range) and numbers (percentage) as appropriate
  2. Abbreviations: CNY Chinese currency (1CNY = 0.15 USD), BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, Scr serum creatinine, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, WBC white blood cell, CVD cardiovascular disease, SUA serum uric acid, MHR Monocyte to high-density lipoprotein ratio
  3. aComparisons for category variables between groups were tested by χ2 test or rank-sum test (ordinal category variables) and comparisons of continuous variables between groups were tested by Student’s t-test or Mann-Whitney test